{"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"ACC"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.1","upperLimit":"30.9","value":"16.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"Non-ACC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Survival estimates will be computed using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.\n\nlapatinib ditosylate: Given orally\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Lapatinib Ditosylate)"}],"paramType":"MEDIAN","populationDescription":"20 participants with ACC, 19 participants with non-ACC.","reportingStatus":"POSTED","timeFrame":"From the date of study enrolment to death or last contact, assessed up to 5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}